Last ¥3,525 JPY
Change Today +120.00 / 3.52%
Volume 2.9M
4519 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 1:00 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

chugai pharmaceutical co ltd (4519) Snapshot

Open
¥3,420
Previous Close
¥3,405
Day High
¥3,585
Day Low
¥3,420
52 Week High
08/18/14 - ¥4,015
52 Week Low
02/5/14 - ¥2,179
Market Cap
2.0T
Average Volume 10 Days
1.4M
EPS TTM
¥93.50
Shares Outstanding
559.7M
EX-Date
06/26/15
P/E TM
37.7x
Dividend
¥52.00
Dividend Yield
1.36%
Current Stock Chart for CHUGAI PHARMACEUTICAL CO LTD (4519)

Related News

No related news articles were found.

chugai pharmaceutical co ltd (4519) Related Businessweek News

No Related Businessweek News Found

chugai pharmaceutical co ltd (4519) Details

Chugai Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in Japan and internationally. Its products in oncology include Avastin, Herceptin, Rituxan, Xeloda, Tarceva, Neutrogin, and Perjeta; bone and joint disease products comprise Actemra, Suvenyl, Edirol, Alfarol, and Bonviva; renal disease products consist of Mircera, Oxarol, and Epogin; and other products, such as Tamiflu, Sigmart, CellCept, Pegasys, and Copegus. The company has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, central nervous system, respiratory diseases, and other diseases. Chugai Pharmaceutical Co., Ltd. has a strategic alliance with Roche; and co-development agreement with Taisho Pharmaceutical Co., Ltd., as well as co-marketing agreement with Taisho Toyama Pharmaceutical Co., Ltd. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

7,023 Employees
Last Reported Date: 01/28/15
Founded in 1925

chugai pharmaceutical co ltd (4519) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: ¥266.0M
President, Chief Operating Officer and Repres...
Total Annual Compensation: ¥74.0M
Compensation as of Fiscal Year 2013.

chugai pharmaceutical co ltd (4519) Key Developments

Chugai Pharmaceutical to Invest SGD 476 Million into its Research Institute in Singapore, Chugai Pharmabody Research

Chugai Pharmaceutical announced that it will invest SGD 476 million from now until 2021 into its research institute in Singapore, Chugai Pharmabody Research. When CPR first set up its corporate laboratory here in 2012 to develop antibody drugs, it planned to pour about SGD 200 million into antibody research over the subsequent five years. The new grant now comes on top on that. The investment will go towards boosting the company's local employee base and antibody research and development pipeline. In addition, it will be expanding physically too. From occupying the fourth floor at the Synapse building at Biopolis Drive, it will now go on to rent more than half of the seventh floor. Chugai aims to accelerate development of new therapeutic antibodies by novel technologies which are currently being built up, while continuing to work on R&D activities with established antibody engineering technologies.

Chugai Pharmaceutical Co. Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal 2015; Announces Unaudited Consolidated Earnings Results for the Year Ended December 31, 2014; Provides Earnings Guidance for the Year Ending December 31, 2015

Chugai Pharmaceutical Co. Ltd. provided dividend guidance for the second quarter ending June 30, 2015. The company forecasts a dividend of ¥26.00 per share for the second quarter of fiscal 2015. For the year ending December 2015, the company forecasts year-end dividend of ¥26.00 per share. The company announced unaudited consolidated earnings results for the year ended December 31, 2014. For the year, the company reported revenues were JPY 461,109 million against JPY 423,652 million a year ago. Operating profit was JPY 75,859 million against JPY 78,738 million a year ago. Profit before taxes was JPY 76,164 million against JPY 76,944 million a year ago. Net income was JPY 52,077 million or JPY 93.38 diluted per share against JPY 51,886 million or JPY 93.35 diluted per share a year ago. Net income attributable to Chugai shareholders was JPY 50,980 million against JPY 50,895 million a year ago. Profit before taxes was JPY 76,164 million against JPY 76,944 million a year ago. Cash flows from operating activities were JPY 37,034 million against JPY 53,521 million a year ago. Purchase of property, plant and equipment was JPY 16,232 million against JPY 11,287 million a year ago. Purchase of intangible assets was JPY 2,935 million against JPY 3,377 million a year ago. For the year ending December 31, 2015, the company expects revenues of JPY 486,500 million, core operating profit of JPY 85,000 million and core earnings per share of JPY 104.42.

Chugai Pharmaceutical Co. Ltd., 2014 Earnings Call, Jan 29, 2015

Chugai Pharmaceutical Co. Ltd., 2014 Earnings Call, Jan 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4519:JP ¥3,525.00 JPY +120.00

4519 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4519.
View Industry Companies
 

Industry Analysis

4519

Industry Average

Valuation 4519 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHUGAI PHARMACEUTICAL CO LTD, please visit www.chugai-pharm.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.